Data-Driven Insights

867 Master Data and Channel Analytics Has Emerged as the Best Solution for 5i Products Under the Final AMP Rule

March 2, 2016   |   Dave Weiss

By now, government price departments are well underway towards implementing the Final Average Manufacturer Price (AMP) Rule recently issued by the Center of Medicare and Medicaid Services (CMS). AMP is the average manufacturer price paid by retail community pharmacies (RCP). One of the key provisions of the sub-regulatory guidance is related to “5i” drugs (i.e., infused, injected, implanted, inhaled, or instilled drugs) that are drugs that are “not generally dispensed“ (NGD) in retail pharmacies but rather at infusion centers, specialty pharmacies, and so on. Even though 5i drugs are not sold into retail, they still require an AMP for other […]

Read More

Tags: , , ,

IntegriChain and Accel-KKR Share Vision for Serving Evolving Channel Analytic Needs of Life Sciences Companies

March 1, 2016   |   Kevin Leininger

Today we announced an equity partnership with Accel-KKR (AKKR) that is very exciting both for IntegriChain and our customers. Both IntegriChain and AKKR share a singular vision to service underserved constituencies in the life sciences industry. Life sciences companies are facing a rapidly evolving marketplace driven by changes across the entire healthcare ecosystem from providers to payers and distribution platforms. Navigating this requires life sciences companies to completely rethink the way they advance and support the patient journey. The days of primary care physicians and retail pharmacies serving branded, pill-based prescription products shipped once per week from wholesalers across the […]

Read More

Tags: ,

IntegriChain at Philly CODEFEST 2016

February 25, 2016   |   Miguel Guerreiro

Drexel University’s College of Computing & Informatics hosted its fourth Philly CODEFEST, a two-day coding competition to transform data into real-world solutions. IntegriChain was a huge part of the event by providing judges and mentors and by hosting a workshop to talk to the students about what technology companies are looking for in co-ops and employees. This is just another instance of our continued effort to promote Philadelphia-area technology, which is really starting to expand in the region. We would like to congratulate everyone who won a prize including team Good Civilianship, who won the Grand Prize, the Student Grand Prize, and […]

Read More

Tags: , , ,

Data… Data… Data…

January 29, 2016   |   Sunay Shah

Everywhere you look, data is being collected and stored in an electronic format. From electronic medical records to the Internet of things, data collection is omnipresent; however, trying to figure out how to extract the maximum value from all of the collected data is a continuous process. Most industries–including consumer marketing, finance, healthcare, and technology–are seeing a revolution in how they analyze data as the amount of data they have at their disposal continues to increase by orders of magnitude. So much so that overall, 90% of the world’s data has been collected in the past two years.* Focusing on […]

Read More

Tags: , , ,

Troubling Results of HRSA’s 2015 Program Integrity Audits Posted on November 25

December 16, 2015   |   Dave Weiss

While we applaud the Health Resources and Services Administration (HRSA) for its efforts to create more transparency in the 340B program through its proposed guidance and program integrity initiative, a quick inspection of the 2015 audit results posted on the Office of Pharmacy Affairs (OPA) website is deeply concerning. As part of this report, HRSA audited 137 covered entities in 2015, which was a 30% increase above 2014. If the results are extrapolated to the universe of 30,000+ covered entities (and their associated contract pharmacies) then the level of potential abuse is far worse than even its harshest critics could […]

Read More

Tags: ,

Renewed Emphasis on Driving the Retail Pharmacy Channel

December 2, 2015   |   Josh Halpern

You might have noticed that we recently announced the release of a new set of channel visualizations focused on the retail pharmacy. In an era when specialty pharmacy so dominates our industry’s headlines, you might be surprised to learn that a growing number of our customers are turning renewed attention and resources to the retail pharmacy channel.  Manufacturers are examining retail pharmacy design and pharmacist engagement with a fresh eye, and some are finding attractive opportunities to improve the patient experience and maximize brand success. First a little history. Back in the 20th century, before the advent of script data, drug […]

Read More

Tags: , ,

IntegriChain Launches New Hybrid Cloud

October 27, 2015   |   Kevin Leininger

We have partnered with Amazon Web Services (AWS) and have big plans to leverage the fastest growing cloud platform on the planet. The rate of growth and innovation in AWS is truly astonishing. I have been in the software business for 25 years and never seen anything quite like it.

Read More

An Itch to Ditch our Co-Lo and Move to the Amazon Web Services (AWS) Platform

July 13, 2015   |   Digesh Kapadia

This was my second year in a row that I attended the AWS Summit in NYC at Jacob Javits. The event coincided with the celebration of 80th birthday of his Holiness the 14th Dalai Lama at the same place, so in some aspect it was a blessed summit. Just like last year, keynote Dr. Werner Vogels, Amazon’s Chief Technology Officer (CTO), touched upon new services they are rolling out, from Elastic File Storage (EFS) to AWS Device Farm and developer tools including AWS CodeCommit, CodePipeline, CodeDeploy, and more. The pace of innovation that happens within Amazon goes to the core of empowerment […]

Read More

Tags: ,

GAO 340B Report: The Debate on Whether 340B Financial Incentives Create “Big Hospitals”

July 9, 2015   |   Dave Weiss

For those of us who monitor the 340B Drug Pricing Program, a fascinating report and industry debate erupted this week over the June 2015 US Government Accountability Office (GAO) Report to Congress entitled “Medicare Part B Drugs: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals." Debate has broken out after the report showed that while charitable and unreimbursed care are in fact higher at 340B hospitals, especially at those with higher Disproportionate Share Hospital (DSH) adjustments, some notable facts and trends in the program have emerged.

Read More

Tags: , ,

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71